A PHASE II MULTI-CENTRE, RANDOMIZED, OPEN LABEL STUDY OF PROLONGED THERAPY WITH SUBCUTANEOUS BORTEZOMIB TWICE MONTHLY ASSOCIATED WITH DEXAMETHASONE, IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER SALVAGE WITH BORTEZOMIB-BASED THERAPY.
Latest Information Update: 26 Mar 2014
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 13 Aug 2013 New trial record